PDF(Pubmed)
Abstract：
UNASSIGNED: This study introduced a novel subtype classification method for endometrial cancer (EC) with mismatch repair deficiency (MMRd) by employing immune status and prognosis as the foundational criteria. The goal was to enhance treatment guidance through precise subtype delineation.
UNASSIGNED: Study Cohort: This study encompassed a cohort of 119 patients diagnosed with MMRd-EC between 2015 and 2022. Analyses using t-tests and Mann-Whitney U-tests were performed to assess prognostic markers and peripheral blood immune cell profiles in patients with MutS deficiency (MutS-d) versus those with MutL deficiency (MutL-d). Logistic regression analysis was used to identify independent risk factors. Bioinformatics Analysis: An online database was used to assess the prognostic implications, immune cell infiltration, and immune checkpoint involvement associated with the deficiency of MutS versus MutL in EC.
UNASSIGNED: Patients with MutL-d exhibited heightened risk factors, including elevated cancer grade and increased myometrial invasion, leading to poorer prognosis and shorter overall survival and progression-free survival. Regarding systemic immune status, patients with MutL-d demonstrated decreased peripheral blood lymphocyte percentage, lymphocyte count, and CD8+ T cell percentage. For local immunity, the infiltration of natural killer cells, CD8+ T cells, and cytotoxic T lymphocytes in the tumor tissue was reduced in patients with MutL-d. Additionally, patients with MutL-d exhibited lower expression of immune checkpoint markers. The composition of immune subtypes and survival outcomes also indicate that patients with MutL-d have a poorer immune status and prognosis than the patients with MutS-d.
UNASSIGNED: Patients with MMRd-EC can be subclassified according to MutS or MutL deficiency. Patients with MutS-d exhibited better immune status, prognosis, and immunotherapy benefits than those with MutL-d. These results can help guide patients to a more precise treatment.
UNASSIGNED: Study Cohort: This study encompassed a cohort of 119 patients diagnosed with MMRd-EC between 2015 and 2022. Analyses using t-tests and Mann-Whitney U-tests were performed to assess prognostic markers and peripheral blood immune cell profiles in patients with MutS deficiency (MutS-d) versus those with MutL deficiency (MutL-d). Logistic regression analysis was used to identify independent risk factors. Bioinformatics Analysis: An online database was used to assess the prognostic implications, immune cell infiltration, and immune checkpoint involvement associated with the deficiency of MutS versus MutL in EC.
UNASSIGNED: Patients with MutL-d exhibited heightened risk factors, including elevated cancer grade and increased myometrial invasion, leading to poorer prognosis and shorter overall survival and progression-free survival. Regarding systemic immune status, patients with MutL-d demonstrated decreased peripheral blood lymphocyte percentage, lymphocyte count, and CD8+ T cell percentage. For local immunity, the infiltration of natural killer cells, CD8+ T cells, and cytotoxic T lymphocytes in the tumor tissue was reduced in patients with MutL-d. Additionally, patients with MutL-d exhibited lower expression of immune checkpoint markers. The composition of immune subtypes and survival outcomes also indicate that patients with MutL-d have a poorer immune status and prognosis than the patients with MutS-d.
UNASSIGNED: Patients with MMRd-EC can be subclassified according to MutS or MutL deficiency. Patients with MutS-d exhibited better immune status, prognosis, and immunotherapy benefits than those with MutL-d. These results can help guide patients to a more precise treatment.
摘要：
■这项研究通过将免疫状态和预后作为基础标准，为具有错配修复缺陷（MMRd）的子宫内膜癌（EC）引入了一种新的亚型分类方法。目标是通过精确的亚型划分来增强治疗指导。
■研究队列：该研究涵盖了2015年至2022年间诊断为MMRd-EC的119名患者的队列。使用t检验和Mann-WhitneyU检验进行分析，以评估MutS缺陷（MutS-d）患者与MutL缺陷（MutL-d）患者的预后标志物和外周血免疫细胞谱。采用Logistic回归分析确定独立危险因素。生物信息学分析：使用在线数据库评估预后影响，免疫细胞浸润，以及与EC中MutS和MutL缺乏相关的免疫检查点参与。
■MutL-d患者表现出升高的危险因素，包括癌症分级升高和肌层浸润增加，导致预后较差，总生存期和无进展生存期较短。关于全身免疫状态，MutL-d患者外周血淋巴细胞百分比降低，淋巴细胞计数,和CD8+T细胞百分比。为了当地豁免权，自然杀伤细胞的浸润,CD8+T细胞，MutL-d患者肿瘤组织中的细胞毒性T淋巴细胞减少。此外,MutL-d患者的免疫检查点标志物表达较低.免疫亚型的组成和生存结果也表明MutL-d患者的免疫状态和预后比MutS-d患者差。
■MMRd-EC患者可以根据MutS或MutL缺陷进行细分。MutS-d患者表现出更好的免疫状态，预后,和免疫疗法的好处比那些与MutL-d。这些结果可以帮助指导患者进行更精确的治疗。
■研究队列：该研究涵盖了2015年至2022年间诊断为MMRd-EC的119名患者的队列。使用t检验和Mann-WhitneyU检验进行分析，以评估MutS缺陷（MutS-d）患者与MutL缺陷（MutL-d）患者的预后标志物和外周血免疫细胞谱。采用Logistic回归分析确定独立危险因素。生物信息学分析：使用在线数据库评估预后影响，免疫细胞浸润，以及与EC中MutS和MutL缺乏相关的免疫检查点参与。
■MutL-d患者表现出升高的危险因素，包括癌症分级升高和肌层浸润增加，导致预后较差，总生存期和无进展生存期较短。关于全身免疫状态，MutL-d患者外周血淋巴细胞百分比降低，淋巴细胞计数,和CD8+T细胞百分比。为了当地豁免权，自然杀伤细胞的浸润,CD8+T细胞，MutL-d患者肿瘤组织中的细胞毒性T淋巴细胞减少。此外,MutL-d患者的免疫检查点标志物表达较低.免疫亚型的组成和生存结果也表明MutL-d患者的免疫状态和预后比MutS-d患者差。
■MMRd-EC患者可以根据MutS或MutL缺陷进行细分。MutS-d患者表现出更好的免疫状态，预后,和免疫疗法的好处比那些与MutL-d。这些结果可以帮助指导患者进行更精确的治疗。
